Should I buy or sell Kamada stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kamada in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" KMDA shares. View KMDA analyst ratings or view top-rated stocks .

What is Kamada's stock price target for 2024?

1 Wall Street analysts have issued 1 year price objectives for Kamada's shares. Their KMDA share price targets range from $11.00 to $11.00. On average, they predict the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 114.4% from the stock's current price. View analysts price targets for KMDA or view top-rated stocks among Wall Street analysts .

How have KMDA shares performed in 2024?

Kamada's stock was trading at $6.12 at the start of the year. Since then, KMDA stock has decreased by 16.2% and is now trading at $5.13. View the best growth stocks for 2024 here .

Are investors shorting Kamada?

Kamada saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 40,300 shares, a decrease of 10.4% from the March 15th total of 45,000 shares. Based on an average daily volume of 23,000 shares, the days-to-cover ratio is currently 1.8 days. Approximately 0.1% of the shares of the company are short sold. View Kamada's Short Interest .

When is Kamada's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 22nd 2024. View our KMDA earnings forecast .

How were Kamada's earnings last quarter?

Kamada Ltd. (NASDAQ:KMDA) issued its quarterly earnings results on Wednesday, March, 6th. The biotechnology company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.04. The biotechnology company earned $36.43 million during the quarter, compared to analysts' expectations of $37.71 million. Kamada had a net margin of 5.81% and a trailing twelve-month return on equity of 5.66%.

What guidance has Kamada issued on next quarter's earnings?

Kamada issued an update on its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $156.0 million-$160.0 million, compared to the consensus revenue estimate of $166.1 million.

What other stocks do shareholders of Kamada own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kamada investors own include Xtrackers California Municipal Bond ETF (CA) , BlackRock (BLK) , Endologix (ELGX) , Chipotle Mexican Grill (CMG) , Athabasca Oil (ATH) , Allergan (AGN) , NIC (EGOV) , Micron Technology (MU) , Teva Pharmaceutical Industries (TEVA) and Aegean Marine Petroleum Network (ANW) .

How do I buy shares of Kamada?

Shares of KMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:KMDA

Kamada (KMDA) Stock Price, News & Analysis

→ “Forget Tesla, this is Elon’s Next Big Thing” (From InvestorPlace) (Ad)

Free KMDA Stock Alerts

$5.13

-0.01 (-0.19%)

(As of 04/15/2024 ET)

Compare

Today's Range: $5.13
▼
$5.36
50-Day Range: $5.13
▼
$6.42
52-Week Range: $4.08
▼
$6.53

Volume: 11,040 shs
Average Volume: 16,271 shs
Market Capitalization: $294.82 million

P/E Ratio: 34.20
Dividend Yield: N/A
Price Target: $11.00

Get Kamada alerts:

Kamada MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 114.4% Upside
$11.00 Price Target
Short Interest: Healthy
0.13% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.07
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 78.26%
From $0.23 to $0.41 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.17 out of 5 stars

Medical Sector

154th out of 928 stocks

Pharmaceutical Preparations Industry

57th out of 428 stocks

3.5

Analyst's Opinion

Consensus Rating
Kamada has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Kamada has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.13% of the float of Kamada has been sold short.
Short Interest Ratio / Days to Cover
Kamada has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Kamada has recently decreased by 10.44%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Kamada does not currently pay a dividend.
Dividend Growth
Kamada does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for KMDA.

2.8

News and Social Media Coverage

News Sentiment
Kamada has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Kamada this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for KMDA on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kamada insiders have not sold or bought any company stock.
Percentage Held by Insiders
36.10% of the stock of Kamada is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 20.38% of the stock of Kamada is held by institutions.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Kamada are expected to grow by 78.26% in the coming year, from $0.23 to $0.41 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Kamada is 34.20, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 142.25.
Price to Earnings Ratio vs. Sector
The P/E ratio of Kamada is 34.20, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 237.87.
Price to Book Value per Share Ratio
Kamada has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

Click here to see the details.

About Kamada Stock (NASDAQ:KMDA)

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

KMDA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

KMDA Stock News Headlines

April 15, 2024 | americanbankingnews.com

Kamada Ltd. (NASDAQ:KMDA) Short Interest Down 10.4% in March

April 12, 2024 | americanbankingnews.com

Kamada (NASDAQ:KMDA) Stock Crosses Below Two Hundred Day Moving Average of $5.47

April 16, 2024 | InvestorPlace (Ad)

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

April 12, 2024 | americanbankingnews.com

Kamada (NASDAQ:KMDA) Stock Price Crosses Below Two Hundred Day Moving Average of $5.47

March 19, 2024 | finance.yahoo.com

KMDA Aug 2024 10.000 call

March 19, 2024 | finance.yahoo.com

KMDA May 2024 5.000 call

March 16, 2024 | finance.yahoo.com

KMDA Apr 2024 10.000 call

March 13, 2024 | finance.yahoo.com

KMDA: Double Digit Growth Anticipated in 2024 with $158 Million in Expected Revenues and $28 Million in Expected Adjusted EBITDA…

April 16, 2024 | InvestorPlace (Ad)

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

March 7, 2024 | benzinga.com

Preview: Kamada's Earnings

March 7, 2024 | markets.businessinsider.com

Strategic Partnerships and Product Portfolio Expansion Poise Kamada for Robust Growth

March 7, 2024 | finance.yahoo.com

Kamada Ltd. (NASDAQ:KMDA) Q4 2023 Earnings Call Transcript

March 6, 2024 | msn.com

Football: Kubo, Kamada exit Champions League as Sociedad, Lazio lose

March 6, 2024 | washingtonpost.com

Kamada: Q4 Earnings Snapshot

March 6, 2024 | investorplace.com

KMDA Stock Earnings: Kamada Beats EPS, Misses Revenue for Q4 2023

March 6, 2024 | globenewswire.com

Kamada Issues 2024 CEO Letter to Shareholders

March 6, 2024 | globenewswire.com

Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability

February 28, 2024 | globenewswire.com

Kamada to Announce Fourth Quarter and Fiscal Year 2023 Financial Results, and Provide 2024 Financial Guidance on March 6, 2024

February 22, 2024 | benzinga.com

Kamada Stock (NASDAQ:KMDA) Dividends: History, Yield and Dates

February 8, 2024 | wsj.com

Kamada Ltd.

January 31, 2024 | stocknews.com

3 Pharma Gems Driving Profits Now

January 12, 2024 | stocknews.com

Will These 3 Pharma Stocks Become Gainers in 2024?

December 8, 2023 | seekingalpha.com

Kamada: Kedrion Deal Locks In Growth

December 7, 2023 | msn.com

KMDA: Amendment and Extension of Kedrab® U.S. Distribution Agreement to Generate at Least $180 Million Over First Four Years…

December 7, 2023 | finance.yahoo.com

KEDRION ANNOUNCES AN EIGHT-YEAR EXTENSION OF THE DISTRIBUTION AGREEMENT WITH KAMADA IN THE US FOR KEDRAB®

December 7, 2023 | marketwatch.com

Kamada Shares Hit 52-Week High After Extending Agreement With Kedrion

November 15, 2023 | finance.yahoo.com

KMDA: $37.9 Million in 3Q23 Revenues; Closes $60 Million Private Placement with FIMI Opportunity Funds…

See More Headlines

Receive KMDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kamada and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/06/2024
Today: 4/15/2024
Next Earnings (Estimated): 5/22/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:KMDA
CUSIP: N/A
CIK: 1567529
Web: www.kamada.com
Phone: (728) 940-6472
Fax: 972-8940-6473
Employees: 378
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $11.00
High Stock Price Target: $11.00
Low Stock Price Target: $11.00
Potential Upside/Downside: +114.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.15
Trailing P/E Ratio: 34.20
Forward P/E Ratio: 22.30
P/E Growth: N/A
Net Income: $8.28 million
Net Margins: 5.81%
Pretax Margin: 5.91%
Return on Equity: 5.66%
Return on Assets: 3.57%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.43
Quick Ratio: 1.64

Sales & Book Value

Annual Sales: $142.52 million
Price / Sales: 2.07
Cash Flow: $0.43 per share
Price / Cash Flow: 12.05
Book Value: $4.25 per share
Price / Book: 1.21

Miscellaneous

Outstanding Shares: 57,470,000
Free Float: 36,726,000
Market Cap: $294.82 million
Optionable: Optionable
Beta: 1.04

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. Amir London (Age 55)
Chief Executive Officer
Comp: $611k
Mr. Chaime Orlev (Age 54)
Chief Financial Officer
Comp: $387k
Mr. Eran Nir (Age 51)
Chief Operating Officer
Comp: $332k
Mr. Jon R. Knight (Age 58)
Vice President of US Commercial Operations
Comp: $307k
Mr. Boris Gorelik (Age 43)
Vice President of Business Development & Strategic Programs
Comp: $410k
Mr. David Tsur (Age 74)
Co-Founder & Independent Deputy Chairman of the Board
Comp: $252k
Mr. Nir Livneh B.A. (Age 44)
L.L.B., VP, General Counsel & Corporate Secretary
Ms. Hanni Neheman (Age 54)
Vice President of Marketing & Sales
Ms. Liron Reshef (Age 52)
Vice President of Human Resources
Ms. Shavit Beladev
Vice President of Kamada Plasma

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

KMDA Stock Analysis - Frequently Asked Questions

Should I buy or sell Kamada stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kamada in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" KMDA shares.
View KMDA analyst ratings or view top-rated stocks.
What is Kamada's stock price target for 2024?: 1 Wall Street analysts have issued 1 year price objectives for Kamada's shares. Their KMDA share price targets range from $11.00 to $11.00. On average, they predict the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 114.4% from the stock's current price.
View analysts price targets for KMDA or view top-rated stocks among Wall Street analysts.
How have KMDA shares performed in 2024?: Kamada's stock was trading at $6.12 at the start of the year. Since then, KMDA stock has decreased by 16.2% and is now trading at $5.13.
View the best growth stocks for 2024 here.
Are investors shorting Kamada?: Kamada saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 40,300 shares, a decrease of 10.4% from the March 15th total of 45,000 shares. Based on an average daily volume of 23,000 shares, the days-to-cover ratio is currently 1.8 days. Approximately 0.1% of the shares of the company are short sold.
View Kamada's Short Interest.
When is Kamada's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 22nd 2024.
View our KMDA earnings forecast.

How were Kamada's earnings last quarter?: Kamada Ltd. (NASDAQ:KMDA) issued its quarterly earnings results on Wednesday, March, 6th. The biotechnology company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.04. The biotechnology company earned $36.43 million during the quarter, compared to analysts' expectations of $37.71 million. Kamada had a net margin of 5.81% and a trailing twelve-month return on equity of 5.66%.
What guidance has Kamada issued on next quarter's earnings?: Kamada issued an update on its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $156.0 million-$160.0 million, compared to the consensus revenue estimate of $166.1 million.
What other stocks do shareholders of Kamada own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Kamada investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Allergan (AGN), NIC (EGOV), Micron Technology (MU), Teva Pharmaceutical Industries (TEVA) and Aegean Marine Petroleum Network (ANW).
How do I buy shares of Kamada?: Shares of KMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KMDA) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Kamada (KMDA) Stock Price, News & Analysis

Kamada MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Kamada Stock (NASDAQ:KMDA)

KMDA Stock Price History

KMDA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

KMDA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™